Mode
Text Size
Log in / Sign up

IVMP plus efgartigimod ranked highest for mRS improvement in autoimmune encephalitis network meta-analysisComparing Different Treatment Options for Patients with Autoimmune Encephalitis

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that IVMP plus efgartigimod ranked highest for mRS improvement, but evidence is limited by observational data.

This network meta-analysis evaluated various acute-phase immunotherapeutic strategies, including IVMP, IVIG, plasma exchange (PE), immunoadsorption (IA), and efgartigimod (EFG), for the treatment of autoimmune encephalitis in 1,359 adults. The primary outcome was the change in the modified Rankin Scale (mRS) following treatment.

The analysis ranked IVMP plus EFG as the most effective regimen for mRS improvement (MD = -0.99; 95% CrI -1.30 to -0.68; SUCRA 95%). IVMP plus IA ranked second (MD = -0.87; SUCRA 88%). Conversely, IVMP plus PE was ranked lowest for mRS improvement (MD = 0.32; SUCRA 0.2%). Regarding safety, IVIG monotherapy was associated with the lowest risk of adverse events (RR = 0.51, 95% CrI 0.24 to 0.97), while IVMP plus PE was associated with the highest risk (RR = 3.10, 95% CrI 0.92 to 9.60).

Authors noted that the evidence for the top-ranked interventions, IVMP plus EFG and IVMP plus IA, is primarily based on observational studies and small sample sizes. Clinical practice should involve individualizing therapy based on disease severity and antibody subtype. While IVIG remains a viable option due to its favorable safety profile, the overall certainty of the findings for newer combinations is limited by the underlying study designs.

How this fits prior evidence

This network meta-analysis addresses a gap in comparing multiple acute-phase immunotherapeutic regimens for autoimmune encephalitis. While prior coverage noted that PLEX and corticosteroids show the highest clinical response rates in chronic inflammatory demyelinating polyradiculoneuropathy, this study provides a comparative ranking of various combinations, including efgartigimod and immunoadsorption, for acute-phase management.

Autoimmune encephalitis is a serious condition where the body's immune system attacks the brain. Because this condition can cause severe issues, doctors must choose the right treatment quickly. This study looked at several different ways to treat the illness, including steroids, special proteins, and blood filtering.

One specific treatment involving steroids and a new drug called efgartigimod showed the best results for improving patient function. Another option using steroids and immunoadsorption also ranked highly. These two methods appeared to help patients recover more effectively than some other common treatments.

While some treatments were more effective, they also had different safety levels. For example, using only certain proteins was found to be very safe for patients. Other combinations, like steroids with plasma exchange, were less effective and carried a higher risk of side effects.

Doctors should still choose treatments based on how sick a patient is and the specific type of antibodies involved. While some newer methods look promising, more research is needed because some of the data comes from smaller groups of people. For now, many doctors still use standard treatments because they are known to be safe.

What this means for you:
Combining steroids with efgartigimod showed the best results for improving patient function in this study.

Common questions

Which treatment was most effective for autoimmune encephalitis?

The combination of methylprednisolone and efgartigimod ranked the highest for improving outcomes. A combination of methylprednisolone and immunoadsorption ranked second. These results are based on a review of 1,359 adults, though the data for these specific top treatments came mostly from observational studies and small sample sizes.

Are there different risks associated with these treatments?

Yes, safety profiles vary between options. Immunoglobulin monotherapy was found to have the lowest risk of side effects. In contrast, the combination of methylprednisolone and plasma exchange was associated with the highest risk of adverse events. You should talk to your doctor about which option is safest for your specific situation.

How do doctors decide which treatment to use?

Doctors should choose a treatment based on the specific severity of the disease and the type of antibodies involved. While some combinations ranked higher for improvement, others were safer. Because every case is unique, treatment plans should be individualized by medical professionals.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Autoimmune encephalitis (AE) is an immune-mediated inflammatory disorder of the central nervous system associated with substantial morbidity. Acute-phase immunotherapy is crucial for improving outcomes, yet the comparative efficacy and safety of available regimens remain unclear. We therefore performed a Bayesian network meta-analysis to compare acute-phase immunotherapeutic strategies for AE. PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to October 2025 for studies evaluating acute-phase immunotherapy in AE. A Bayesian network meta-analysis was conducted. The primary outcome was change in the modified Rankin Scale (mRS) after treatment; adverse events were secondary outcomes. Effects were expressed as mean differences (MD) and risk ratios (RRs) with 95% credible intervals (CrIs). The surface under the cumulative ranking curve (SUCRA) was used to rank interventions. Eleven studies (1,359 patients) were included, evaluating seven strategies: intravenous methylprednisolone (IVMP), intravenous immunoglobulin (IVIG), IVMP+IVIG, IVMP+plasma exchange (PE), IVMP+IVIG+PE, IVMP+immunoadsorption (IA), and IVMP+efgartigimod (EFG). For efficacy, IVMP+EFG ranked highest in mRS improvement among the included regimens (MD = −0.99, 95% CrI −1.30 to −0.68; SUCRA = 95%), followed by IVMP+IA (MD = −0.87; SUCRA = 88%). IVMP+PE ranked lowest (MD = 0.32; SUCRA = 0.2%). For safety, IVIG monotherapy had the lowest adverse-event risk (RR = 0.51, 95% CrI 0.24 to 0.97), whereas IVMP+PE had the highest risk (RR = 3.10, 95% CrI 0.92 to 9.60). Acute-phase immunotherapy for AE should be individualized by disease severity and antibody subtype. Consistent directional findings were observed in the anti-NMDAR subgroup and, separately, in the subgroup with baseline mRS ≥3. IVMP+EFG and IVMP+IA ranked favorably for short-term functional improvement, although the evidence was based mainly on observational studies and small sample sizes. IVIG remained a reasonable option given its favorable safety profile. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251085606, identifier CRD420251085606.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.